Aditya Birla SL Small Cap Fund
The Scheme seeks to generate consistent long-term capital appreciation by investing predominantly in equity and equity related securities of Small cap companies.
Growthvine rating: 2/5 — ranked #29 of 37 in category.
Fund basics
| Category | Equity: Small Cap |
|---|
| NAV | ₹100.79 (as of 2026-08-21) |
|---|
| AUM | ₹5,731 Cr |
|---|
| Expense ratio | 1.57% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Abhinav Khandelwal |
|---|
| Exit load | 1% for redemption within 90 days |
|---|
Performance & risk
| 5-year annualised return | 12.56% |
|---|
| Sharpe ratio | 0.52 |
|---|
| Standard deviation | 19.95% |
|---|
| Max drawdown | -69.70% |
|---|
| Alpha | 0.75 |
|---|
| Beta | 0.9 |
|---|
Over 5 years, captured 85.5% of NIFTY Smallcap 250's upside and 88.4% of its downside.
Market cap allocation
| Large cap | 2.1% |
|---|
| Mid cap | 13.4% |
|---|
| Small cap | 84.5% |
|---|
Concentration
| Top 5 holdings | 12.8% |
|---|
| Top 10 holdings | 23.0% |
|---|
| Total holdings | 88 |
|---|
| Index overlap | 24.8% |
|---|
| Active share | 75.2% |
|---|
Top holdings
- Sai Life Sciences Limited — 2.9%
- Reverse Repo — 2.8%
- Navin Fluorine International Limited — 2.7%
- Ujjivan Small Finance Bank Limited — 2.7%
- Radico Khaitan Ltd. — 2.2%
- Shaily Engineering Plastics Ltd. — 2.2%
- Karur Vysya Bank Ltd. — 2.1%
- CCL Products (India) Ltd. — 2.1%
- Dr. Lal Pathlabs Limited — 2.0%
- RBL Bank Limited — 2.0%
Top sectors
- Banking & Financial — 10.9%
- Pharma & Biotech — 9.9%
- Automobile — 9.4%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 19.0% | Q1 (Top) | #8 of 34 |
| 2025 | -3.7% | Q2 | #14 of 30 |
| 2024 | 21.5% | Q4 (Bottom) | #23 of 28 |
| 2023 | 39.4% | Q3 | #16 of 24 |
| 2022 | -6.5% | Q4 (Bottom) | #22 of 22 |